Response to sorafenib treatment in advanced metastatic thyroid cancer;Resposta ao tratamento com sorafenibe em pacientes com carcinoma metastático de tireoide

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 58, Issue 1, 2014, Pages 37-41

  Pitoia, Fabian ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Cancer; Metastasis; Sorafenib; Thyroid

Indexed keywords

ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; RADIOACTIVE IODINE; SORAFENIB; THYROGLOBULIN;

AGED; ANALOGS AND DERIVATIVES; BLOOD; BONE TUMOR; CANCER STAGING; CARCINOMA, PAPILLARY; CHEMICALLY INDUCED; COMPASSIONATE USE; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; LUNG TUMOR; MALE; MIDDLE AGED; PATHOLOGY; SECONDARY; THYROID NEOPLASMS; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CARCINOMA, PAPILLARY; COMPASSIONATE USE TRIALS; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; IODINE RADIOISOTOPES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; THYROGLOBULIN; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 84897425050     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/0004-2730000002839     Document Type: Article

References (22)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer. 1998;83(12):2638-48.
3. Eustatia-Rutten CF, Corssmit EP, Biermasz NR, Pereira AM, Romijn JA, Smit JW. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2006;91(1):313-9.
4. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91(8):2892-9.
5. Hodak SP, Carty SE. Radioiodine-resistant differentiated thyroid cancer: hope for the future. Oncology. 2009;23(9):775-6.
6. Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW, et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxyd-glucose-positron emission tomography scanning. J Clin Endocrinol Metab. 2006;91(2):498-505.
7. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167-214.
8. Pitoia F, Ward L, Wohllk N, Friguglietti C, Tomimori E, Gauna A, et al. Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer. Arq Bras Endocrinol Metabol. 2009;53(7):884-7.
9. Brose MS, Smit J, Capdevila J, Elisei R, Nutting C, Pitoia F, et al. Approach to the patient with advanced differentiated thyroid cancer. Expert Rev Anticancer Ther. 2012;12(9):1137-47.
10. Pacini F, Ito Y, Luster M, Pitoia F, Robinson B, Wirth L. Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions. Expert Rev Endocrinol Metab. 2012;7(5):541-54.
11. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-47.
12. Kim A, Balis FM, Widemann BC. Sorafenib and sunitinib. Oncologist. 2009;14(8):800-5.
13. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008;26(29):4714-9.
14. Keefe SM, Troxel AB, Rhee S. Phase II trial of sorafenib in patients with advanced thyroid cancer. J Clin Oncol. 2011;29(Suppl. 15), abstract 5562.
15. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 2009;27(10):1675-84.
16. Ahmed M, Barbachano Y, Riddell A, Hickey J, Newbold KL, Viros A, et al. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol. 2011;165(2):315-22.
17. Hoftijzer H, Heemstra KA, Morreau H, Stokkel MP, Corssmit EP, Gelderblom H, et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol. 2009;161(6):923-31.
18. Capdevila J, Iglesias L, Halperin I, Segura A, Martínez-Trufero J, Vaz MA, et al. Sorafenib in metastatic thyroid cancer. Endocr Relat Cancer. 2012;19(2):209-16.
19. Brose MS, Nutting CM, Sherman SI, Shong YK, Smit JW, Reike G, et al. Rationale and design of decision: a double-blind, randomized, placebo controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. BMC Cancer. 2011;11:349.
20. Cabanillas ME, Hu MI, Durand JB, Busaidy NL. Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer. JThyroid Res. 2011;2011:985780. doi: 10.4061/2011/985780.
21. Chintalgattu V, Ai D, Langley RR, Zhang J, Bankson JA, Shih TL, et al. Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress. J Clin Invest. 2010;120(2):472-84.
22. th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL at 3:20pm CDT (Abstract #4).